Onno van de Stolpe: no deals without a vision

It is unusual for a biotech company to have the same CEO throughout its evolution from a startup to a publicly listed company and a partner with a big pharma giant. Ablynx, for instance, had a couple of CEO’s until it was acquired by Sanofi. In this last part of Week 4, you will hear the secret recipe of Onno van de Stolpe who remained in charge of his company for more than twenty years.